Skip to main content
. Author manuscript; available in PMC: 2023 Jan 23.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2022 Jun 4;114(4):725–737. doi: 10.1016/j.ijrobp.2022.05.037

Fig. 1.

Fig. 1.

Association of prostate cancer–specific extracellular vesicle levels with tumor burden in oligometastatic and metastatic prostate cancer. (A) Representative scatterplots showing nanoscale flow cytometric detection of PSMA- and STEAP1-positive extracellular vesicles (EVs) from plasma of 1 patient with oligometastatic castration-resistant prostate cancer (omCRPC). (B, C) Comparisons are shown in levels of PSMA-positive (B) and STEAP1-positive EVs (C) in localized prostate cancer after radical prostatectomy (n = 22), omCRPC (n = 79), and metastatic castration-resistant prostate cancer (n = 40). ***P < .001 by Kruskal-Wallis test.